Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jennifer Peleshok"'
Autor:
Heike Jung, Manige Konig, Joanna Van, Jennifer Peleshok, Enzo Bonora, M. Angelyn Bethel, Sohini Raha, Juan P. Frias, David A. Cox, Jarrett Meyer
Publikováno v:
Diabetes Therapy
Background Gastrointestinal (GI) events are the most frequent treatment-emergent adverse events (TEAEs) reported for glucagon-like peptide-1 receptor agonist therapies. This post hoc analysis of the AWARD-11 phase 3 trial assessed the GI tolerability
Autor:
Christophe De Block, Clifford Bailey, Carol Wysham, Andrea Hemmingway, Sheryl Elaine Allen, Jennifer Peleshok
Publikováno v:
Diabetes, obesity & metabolism
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GLP-1) receptor agonist approved in the United States as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes and unde
Publikováno v:
Diabetes. 71
Five Phase 3 SURPASS trials have shown robust efficacy of novel dual GIP/GLP-1 receptor agonist, tirzepatide, in glycaemic control and body weight (BW) loss in adults with Type 2 Diabetes (T2D) . A key secondary endpoint investigated the effect of ti
Autor:
ROSIRENE PACZKOWSKI, MEREDITH HOOG, JENNIFER PELESHOK, MARIA YU, AHONG HUANG, BRENDAN LIMONE, JANNA MANJELIEVSKAIA
Publikováno v:
Diabetes. 71
A retrospective, observational analysis of administrative claims data from the IBM MarketScan Databases assessed adherence and persistence among GLP-1 RA naive adult patients with T2D newly initiating dulaglutide (DU) or oral semaglutide (OS) between
Publikováno v:
Diabetes. 71
Results of SURPASS-1 through -5 trials have shown robust efficacy of novel dual GIP/GLP-1 receptor agonist tirzepatide (TZP) in people with type 2 diabetes. To understand whether glucose-lowering effect of tirzepatide depends on the duration of diabe
Publikováno v:
Clinical therapeutics. 44(6)
To describe clinical characteristics and treatment outcomes for early or late initiation of dulaglutide therapy in patients with type 2 diabetes.This retrospective, claims-based analysis evaluated adults with type 2 diabetes, ≥1 claim for dulagluti
Publikováno v:
Diabetes. 70
This retrospective, observational study assessed glycemic control over a 6-month follow-up among patient cohorts with T2D who initiated dulaglutide (DU) 0.75 mg or 1.5 mg following use of either 1, 2 or 3+ oral antihyperglycemic drugs (OAD) during th
Autor:
Juan P. Frias, Enzo Bonora, Heike Jung, Manige Konig, Sohini Raha, David A. Cox, Joanna Van, Jennifer Peleshok
Publikováno v:
Diabetes. 70